Job performance in chronic hepatitis C virus patients treated with pegylated interferon-α2b plus ribavirin: an observational study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2396-832X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Job performance in chronic hepatitis C virus patients treated with pegylated interferon-α2b plus ribavirin: an observational study ; volume:2 ; number:1 ; day:21 ; month:2 ; year:2017 ; pages:1-10 ; date:12.2017
Translational medicine communications ; 2, Heft 1 (21.2.2017), 1-10, 12.2017
- Creator
-
Malaguarnera, Giulia
- Contributor
-
Bertino, Gaetano
Greco, Carmela
Gagliano, Caterina
Motta, Massimo
Chisari, Giuseppe
Rapisarda, Venerando
Nunnari, Giuseppe
Vecchio, Michele
Drago, Filippo
Malaguarnera, Michele
SpringerLink (Online service)
- DOI
-
10.1186/s41231-016-0010-4
- URN
-
urn:nbn:de:1111-201703151001
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Malaguarnera, Giulia
- Bertino, Gaetano
- Greco, Carmela
- Gagliano, Caterina
- Motta, Massimo
- Chisari, Giuseppe
- Rapisarda, Venerando
- Nunnari, Giuseppe
- Vecchio, Michele
- Drago, Filippo
- Malaguarnera, Michele
- SpringerLink (Online service)
Other Objects (12)
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients
The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients
The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
Heterogeneity of hepatitis C virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Heterogeneity of hepatitis C-virus in genotype 1 patients treated with the combination therapy of pegylated interferon and ribavirin
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy
Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study
Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis
Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients
The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin